Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BTZ043 Racemate (Benzothiazinone 10526038) is a decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitor, used as a new antimycobacterial agent.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 183.00 | |
50 mg | In stock | $ 322.00 | |
100 mg | In stock | $ 538.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | BTZ043 Racemate (Benzothiazinone 10526038) is a decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitor, used as a new antimycobacterial agent. |
In vitro | By targeting decaprenylphosphoryl-β-D-ribose 2'-epimerase, BTZ043 abolishes the formation of decaprenylphosphoryl arabinose, leading to cell lysis and death of Mycobacterium tuberculosis. BTZ043 displays similar activity against all clinical isolates of M. tuberculosis, including multidrug-resistant and extensively drug-resistant strains. BTZ043 displays significant activity against M. tuberculosis H37Rv and Mycobacterium smegmatis with MIC of 1 ng/mL (2.3 nM) and 4 ng/mL (9.2 nM), respectively, which is more potent than those of the existing tuberculosis (TB) drugs isoniazid (INH) and ethambutol (EMB) with MIC of 0.02-0.2 μg/mL and 1-5 μg/mL, respectively. BTZ043 is less effective in two different model systems (auxotrophy and starvation) involving metabolically inert M. tuberculosis, indicating that BTZ043 blocks a step in active metabolism similar to isoniazid (INH). BTZ043 treatment in M. smegmatis cells decreases the growth rate rapidly followed by a swelling of the poles and lysis of the cells after a few hours, which is similar but delayed in M. tuberculosis. [1] BTZ043 (1/4 MIC 0.375 ng/mL) in combination with TMC207 (1/4 MIC 20 ng/mL) has a stronger cidal effect on M. tuberculosis but not BTZ-resistant M. tuberculosis mutant than TMC207 alone at a concentration of 80 ng/mL. [2] |
In vivo | In a mouse model of chronic tuberculosis, administration of BTZ043 at 37.5 mg/kg or 300 mg/kg for 4 weeks reduces the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively. [1] |
Synonyms | BTZ044, BTZ10526038, Benzothiazinone 10526038 |
Molecular Weight | 431.39 |
Formula | C17H16F3N3O5S |
CAS No. | 957217-65-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 21 mg/mL (48.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BTZ043 Racemate 957217-65-1 Microbiology/Virology Others Antibacterial DprE1 Benzothiazinone10526038 inhibit Benzothiazinone-10526038 BTZ-044 BTZ044 Inhibitor BTZ-043 Racemate BTZ-043 BTZ-10526038 BTZ043 BTZ 043 tuberculosis BTZ10526038 Benzothiazinone 10526038 BTZ 10526038 BTZ 044 Bacterial inhibitor